Boca Raton, FL, US, April 7, 2021 – Akron Biotech, a leading developer and manufacturer of cGMP-compliant ancillary materials for cell and gene therapy development and commercialization, today announces the appointment of a new Scientific Advisory Board. The board is comprised of world-leading scientists and experts in the cell and gene therapy field. It will
Safety First: Methods of virus inactivation for increased safety of advanced therapies
Regulatory agencies around the world have been steadily increasing pressure on cell, gene, and tissue-engineered drug development companies to put safety first and find ways to control the inherent risks present in many of the raw materials used in the downstream processing of their advanced therapies. The industry has been largely transitioning away from animal-derived
Cryopreservation During the Holidays
As the holidays approach, tissue and cell labs around the globe have to start thinking about cryopreservation. This critical procedure can be overwhelming: What media should I use? What type of cryoprotectant is optimal for my cell type? What is the appropriate freezing rate? At what temperature is plunging appropriate? How about adequate thawing rates?
Akron Biotech Signs Agreement with Synairgen plc to Supply Interferon-beta for COVID-19 Treatment
Akron Biotech Signs Agreement with Synairgen plc to Supply Interferon-beta for COVID-19 Treatment BOCA RATON, FL – October 19, 2020 – Akron Biotechnology today announced it has signed an agreement with Synairgen plc (LSE: SNG) for the provision of SNG001, Synairgen’s wholly-owned inhaled interferon beta (IFN-beta) therapeutic candidate for the treatment of COVID-19 patients. Akron
COVID-19 Response
Akron Biotech is committed to help defeat COVID-19 – Together we cure Coronavirus disease 2019 (COVID-19) is a pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Symptoms tend to appear 2-14 days after exposure to the virus and can range from mild to severe, with some patients requiring  hospitalization1. In response to this
Building a resilient cell and gene therapy industry in the face of COVID-19
The disruption to daily life from our collective preventative measures against the global SARS-CoV-2 outbreak is obvious to most. Many industries are being held back and we will likely see long-term or permanent effects from the shifts happening with social interaction in and out of the workplace. What may not be so obvious in the
The importance of cytokine and growth factor purity in cell therapy development and manufacturing
Today, it is more important than ever to understand the quality of ancillary materials in the cell and gene therapy supply chain. As part of a therapy developer’s risk and impact assessment, each material must be evaluated for purity, lot-to-lot consistency, and potential impact on the drug product. Because of its outsized impact on cost
Building a Robust Supply Chain to Enable Cell and Gene Therapy Development
In the burgeoning cell and gene therapy market, companies at all stages of pre-clinical and clinical development are faced with a similar set of challenges of producing effective, standardized, and compliant therapies. The novelty of these technologies combined with the rigorous quality controls surrounding the materials and production process require a specialized approach for starting
COVID-19 Virus Notice
A Note to Our Valued Partners Regarding COVID-19 As we continue to deal with the challenges and uncertainty of Covid-19 Virus, our priority is to ensure the safety of our employees while minimizing any potential impact to our valued customers and partners. Therefore, we are taking all the necessary precautions to ensure that our
A note to our valued partners regarding COVID-19
A Letter From Our CEO Dear Valued Partner, In challenging and uncertain times, it’s our collective responsibility to take care of one another. At Akron Biotech, our top priority is always our customers and our staff. That’s why we are closely monitoring the COVID-19 situation around the clock, ensuring that we take all necessary precautions